NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-22 19:30இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Rossari Q2 FY27 Earnings Call: Revenue Up 19% YoY to ₹697.6 Cr, Saudi Land Lease Approved
Rossari Biotech released the earnings call transcript for Q2 FY27, reporting its highest-ever quarterly revenue of ₹697.6 Cr (up 19% YoY) and EBITDA of ₹87 Cr (up 21% YoY, 12.5% margin). Net profit rose 5.5% YoY to ₹38.9 Cr with diluted EPS of ₹7.02. The company announced board approval for leasing land to set up a Greenfield manufacturing facility in Saudi Arabia via its subsidiary. Net working capital improved by 10 days to 87 days, supported by better collections and inventory rationalization.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari Biotech submitted the complete transcript of its Q2 FY27 earnings conference call held on October 19, 2026.
ஏன் இது முக்கியம்Demonstrates record operational run-rate (~₹700 Cr/quarter), sequential margin recovery to 12.5%, and concrete progress on international expansion into Saudi Arabia.
Q2 FY27 Revenue: Rs. 697.6 கோடிQ2 FY27 EBITDA: Rs. 87 கோடிQ2 FY27 PAT: Rs. 38.9 கோடிNet Working Capital: 87 நாட்கள்Q2 வருவாய் vs TTM வருவாய்: ~27.4%
📅 குறுகிய காலம்Market sentiment should stay supported by sequential margin expansion (gross margin at 31.6%, up ~200 bps QoQ) and record quarterly revenue run rate.
📈 நீண்ட காலம்The Saudi Arabia Greenfield facility offers direct access to key petrochemical raw materials and Middle East oil and gas demand, potentially lifting ROCE as new capacities ramp up.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility in petrochemical/oleo feedstocks
Geopolitical friction impacting freight and logistics
👀 கவனிக்க வேண்டியவை
Track the disclosure of project details, capex outlays, and return targets for the Greenfield facility in Saudi Arabia, along with sustained working capital containment below 90 days.
Rossari Biotech Reports Q2 FY27 Revenue Up 19% to ₹697.6 Cr, EBITDA Up 20.9% to ₹87 Cr
Rossari Biotech reported its highest-ever quarterly revenue of ₹697.6 crore for Q2 FY27, up 19.0% YoY, alongside record quarterly EBITDA of ₹87.0 crore, growing 20.9% YoY. Profit After Tax rose modestly to ₹38.9 crore, impacted by higher depreciation from ongoing capital investments. The company witnessed robust export sales reaching ₹216.4 crore (up 33.8% YoY) and generated ₹131 crore in operating cash flows. In addition, the Board approved leasing land for a greenfield facility in Saudi Arabia, while net debt declined by ₹60 crore to ₹221 crore since March 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari reported record quarterly revenue and EBITDA for Q2 FY27 and approved land leasing for a greenfield manufacturing unit in Saudi Arabia.
ஏன் இது முக்கியம்Demonstrates operational scaling, balance sheet deleveraging (net debt down ₹60 Cr), and an expanding international manufacturing presence.
📅 குறுகிய காலம்Solid operational results and deleveraging provide near-term earnings support following a 32% 12-month share price decline.
📈 நீண்ட காலம்Expansion into Saudi Arabia and commissioning of dedicated storage facilities position Rossari well to sustain its 15% long-term growth ambitions.
⚠ அபாய எச்சரிக்கைகள்
Higher depreciation from capex muting PAT growth
Raw material price volatility impacting gross margins
Geopolitical uncertainties affecting export freight and supply chains
👀 கவனிக்க வேண்டியவை
Track the execution timeline and capex guidance for the greenfield facility in Saudi Arabia, as well as margin sustainability amidst volatile raw material prices.
Rossari Biotech Q2FY27 Revenue Rises 19% YoY to ₹697.6 Cr; Approves Land Lease for KSA Plant
Rossari Biotech released its Q2 & H1 FY27 investor presentation, reporting highest-ever quarterly revenue of ₹697.6 crore, up 19.0% YoY, and EBITDA of ₹87.0 crore, up 20.9% YoY. PAT rose marginally by 5.4% YoY to ₹38.9 crore, constrained by higher depreciation from ongoing investments. The company also announced Board approval for leasing land via wholly owned subsidiary RILC to build a greenfield manufacturing unit in Saudi Arabia. Net working capital cycle improved to 86 days from 97 days in March 2026, and net debt declined to ₹221 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari delivered solid top-line and operating profit growth in Q2FY27 and formally approved land lease for setting up an overseas manufacturing base in Saudi Arabia.
ஏன் இது முக்கியம்Demonstrates operating leverage and export traction in specialty chemicals while expanding geographic footprint into the Middle East to de-risk domestic concentration.
📅 குறுகிய காலம்Stable performance with revenue and EBITDA reaching record quarterly highs may support market sentiment, although PAT growth remains moderate due to depreciation.
📈 நீண்ட காலம்Expanding presence into KSA along with commissioning of new product lines and storage facilities supports multi-year revenue growth targets of ₹3,500 Cr.
⚠ அபாய எச்சரிக்கைகள்
Input cost volatility and delayed raw material pass-through
Execution and regulatory risks associated with the greenfield facility in Saudi Arabia
High depreciation burden dampening near-term net earnings
👀 கவனிக்க வேண்டியவை
Track capex updates and timeline disclosures for the newly approved Saudi Arabia manufacturing plant, along with margin trajectory in upcoming quarters.
Rossari Biotech Approves Land Lease for Greenfield Facility in Saudi Arabia; Reports H1 FY27 Results
Rossari Biotech's Board approved the leasing of land by its wholly owned subsidiary, Rossari International Limited Company, to set up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). Total capex and project outlay are yet to be finalised and placed before the Board. On the financial front, standalone profit before tax for H1 FY27 rose 19.6% YoY to ₹92.57 Cr compared to ₹77.42 Cr in H1 FY26, alongside operating cash flow generation of ₹87.66 Cr. Five reviewed subsidiaries contributed ₹1,080.17 Cr in revenue and ₹18.99 Cr in PAT for H1 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari approved leasing land in Saudi Arabia for greenfield manufacturing and released H1 FY27 financials.
ஏன் இது முக்கியம்Establishes a local production base in the MENA region, supporting the company's international expansion and reducing cross-border freight costs.
Standalone H1 FY27 Profit Before Tax: ₹925.74 millionStandalone Operating Cash Flow H1 FY27: ₹876.62 millionReviewed Subsidiaries H1 Revenue: ₹10,801.73 millionCapital Outlay for Saudi Facility: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Positive sentiment from solid standalone cash generation and continued operational scaling into international markets.
📈 நீண்ட காலம்Setting up manufacturing in Saudi Arabia aligns with Rossari's stated MENA expansion strategy, helping diversify geographic presence and capture local market demand.
⚠ அபாய எச்சரிக்கைகள்
Capex size and financing mode for the Saudi greenfield facility are not yet disclosed
Overseas project execution and cross-border regulatory risks in KSA
👀 கவனிக்க வேண்டியவை
Track subsequent Board disclosures detailing the capital expenditure, production capacity, and completion timelines for the Saudi Arabia greenfield facility.
Rossari Biotech Q1 FY27: Record Quarterly Revenue of ~₹700 Cr, Up 28% YoY
Rossari Biotech achieved its highest-ever quarterly revenue of approximately ₹700 crore in Q1 FY27, representing a 28% YoY growth. The Home, Personal Care and Performance Chemicals (HPPC) segment was the primary driver, crossing the ₹550 crore milestone. While net debt reduced to ₹248 crore from ₹280 crore in March 2026, interest costs rose to ₹11 crore as previous CAPEX projects were capitalized. Management is focusing on B2B scaling and international expansion, including a new greenfield plant in Thailand and a planned entry into Saudi Arabia.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a heavy investment phase to an operational phase, with record revenues now being supported by recently commissioned capacities.
ஏன் இது முக்கியம்The scale-up to a ₹700 Cr quarterly revenue base (approx. 29% of TTM revenue) demonstrates successful integration of acquisitions and capacity expansions, though margin improvement remains the next critical milestone.
📅 குறுகிய காலம்The market is likely to react positively to the record revenue and debt reduction, though the rise in interest costs may temper immediate bottom-line expectations.
📈 நீண்ட காலம்Structural growth is supported by a 367,100 MTPA capacity and expansion into Southeast Asia and MENA regions, targeting a long-term revenue potential of ₹3,500 Cr.
⚠ அபாய எச்சரிக்கைகள்
Margin pressure from raw material (Ethylene Oxide) pricing
Intense competition in the specialty chemicals segment
Rising interest costs impacting net profit
👀 கவனிக்க வேண்டியவை
Monitor the utilization levels of the ethoxylation and MDEA plants over the next 12 months, as management expects these to drive margin recovery toward normalized levels.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rossari Biotech Shareholders Approve FY26 Dividend and Material RPT with Unitop Chemicals
Rossari Biotech concluded its 17th Annual General Meeting on July 20, 2026, where shareholders approved all eight proposed resolutions with over 99.99% majority. Key approvals include the adoption of FY26 financial statements, declaration of a dividend, and a material related party transaction (RPT) with Unitop Chemicals Private Limited. The company confirmed that dividends will be credited to eligible members within 10 working days. Additionally, the appointment and re-appointment of three directors, including two independent directors, were ratified.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has received formal shareholder mandate for its FY26 financial results, dividend payouts, and critical related-party business dealings with its subsidiary/associate Unitop Chemicals.
ஏன் இது முக்கியம்The approval of the material RPT with Unitop Chemicals is significant as Rossari is investing INR 128 Cr in Unitop to expand ethoxylation capacity, which is a core part of its growth strategy to reach a revenue potential of INR 3,500 Cr.
Dividend Credit Timeline: 10 working daysRPT Approval (Votes in Favor): 99.9961%Total Shareholders on Record Date: 89,110Corporate Representative Shareholding: 14.87%
📅 குறுகிய காலம்The stock is likely to remain neutral as the AGM outcomes were in line with expectations and no major negative surprises were reported.
📈 நீண்ட காலம்The long-term focus remains on the company's ability to scale its recently commissioned 367,100 MTPA capacity and maintain its 15% core EBITDA margins in the B2B segment.
⚠ அபாய எச்சரிக்கைகள்
Related-party transactions with Unitop Chemicals
Intense competition in the specialty chemicals segment restricting pricing power
👀 கவனிக்க வேண்டியவை
Investors should verify the receipt of the FY26 dividend in their registered bank accounts within the next 10 working days and monitor the execution of the 367,100 MTPA capacity scale-up mentioned in the Chairman's address.
Rossari Biotech delivered a robust Q1 FY27 with consolidated revenue growing 28% YoY to Rs 697.2 crore, marking its highest-ever quarterly performance. EBITDA grew 19% to Rs 80.6 crore, although margins contracted slightly to 11.6% from 12.5% in the previous year. Net profit (PAT) saw a modest 4% increase to Rs 35.1 crore. The company also announced the establishment of a 5,000 MTPA greenfield blending facility in Thailand to strengthen its Southeast Asian presence.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari has achieved record-high quarterly revenue and EBITDA while initiating localized manufacturing in Southeast Asia via a new Thailand facility.
ஏன் இது முக்கியம்The strong top-line growth across all segments indicates successful market penetration and scaling of recently added capacities, though the lag in PAT growth suggests rising operational or financial costs.
📅 குறுகிய காலம்The record revenue and EBITDA are likely to be viewed positively by the market, though the narrow 4% PAT growth may limit the upside in the immediate term.
📈 நீண்ட காலம்The expansion into Thailand and the monetization of non-core assets support a leaner, more globalized business model, aligning with the company's target of Rs 3,500 Cr revenue potential.
⚠ அபாய எச்சரிக்கைகள்
EBITDA margin contraction of 90 bps YoY
PAT growth (4%) significantly lagging revenue growth (28%)
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization levels of the new Thailand facility and the company's ability to pass through raw material costs to recover EBITDA margins toward the 12-13% range.
Rossari Biotech Q1 FY27: Revenue Grows 28% to ₹697 Cr; New 5,000 MTPA Thailand Facility Commissioned
Rossari Biotech reported a strong 28.2% YoY revenue growth to ₹697.2 Cr in Q1 FY27, driven by robust demand across its core HPPC, Textile, and Animal Health segments. While EBITDA grew 18.7% to ₹80.6 Cr, consolidated margins contracted by 90 bps to 11.6% due to higher operating costs and flat performance in the B2C segment. A key strategic milestone was the commissioning of a 5,000 MTPA greenfield blending facility in Thailand to serve Southeast Asia. The company also continued its non-core asset monetization by selling its Andheri office during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari has transitioned from domestic-heavy manufacturing to establishing an international production footprint in Thailand while delivering high double-digit top-line growth.
ஏன் இது முக்கியம்The 28% revenue growth confirms strong market share gains in specialty chemicals, while the Thailand facility improves supply-chain efficiency for the Southeast Asian market, supporting the company's ₹3,500 Cr revenue potential target.
Q1 வருவாய்: ₹697.2 கோடிRevenue vs TTM: ~29%Thailand Capacity: 5,000 MTPAEBITDA லாப வரம்பு: 11.6%YoY Revenue Growth: 28.2%Finance Costs: ₹11.0 கோடி
📅 குறுகிய காலம்The market is likely to react positively to the strong revenue beat and international expansion, though the 90 bps margin compression and high finance costs may temper the upside.
📈 நீண்ட காலம்The company is structurally positioned for growth with a diversified portfolio and new international capacity; achieving optimal utilization of its massive 387,100 MTPA total capacity is the key long-term value driver.
⚠ அபாய எச்சரிக்கைகள்
Margin contraction of 90 bps YoY
93% spike in finance costs
Flat performance in Institutional and B2C segments
👀 கவனிக்க வேண்டியவை
Monitor the capacity utilization of the new Thailand facility and the 367,100 MTPA domestic capacity to see if it drives ROCE back toward historical levels. Watch for margin recovery in the B2C and Institutional segments, which remained flat this quarter.
31.8% YoY Revenue Growth in Q1 FY27; Rossari Reports Standalone PAT of Rs 34.27 Cr
Rossari Biotech reported a strong year-on-year standalone performance for Q1 FY27, with revenue rising 31.8% to Rs 482.28 Cr compared to Rs 365.76 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 30.6% YoY to Rs 34.27 Cr. However, performance weakened sequentially, with revenue down 6.5% and PAT down 37.4% from Q4 FY26 levels. The company also announced an internal restructuring to move its Saudi Arabian subsidiary under its Singapore entity to streamline global operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுRossari reported its Q1 FY27 financial results and initiated an internal corporate restructuring to consolidate overseas subsidiaries under a single Singapore-based holding platform.
ஏன் இது முக்கியம்The strong YoY growth indicates robust demand in specialty chemicals, though the sequential decline suggests margin volatility or seasonal softness. The restructuring simplifies regulatory reporting for international operations.
Standalone Revenue (Q1 FY27): Rs 482.28 கோடிStandalone PAT (Q1 FY27): Rs 34.27 கோடிYoY Revenue Growth: 31.8%QoQ PAT Growth: -37.4%Q1 வருவாய் vs TTM வருவாய்: ~20.1%
📅 குறுகிய காலம்The stock may see positive sentiment from the strong YoY growth figures, although the sharp sequential drop in PAT might lead to some profit-taking or caution.
📈 நீண்ட காலம்The company remains focused on scaling its 367,100 MTPA capacity to reach a target revenue of Rs 3,500 Cr. Success depends on maintaining margins in the B2B specialty segment amidst raw material volatility.
⚠ அபாய எச்சரிக்கைகள்
Significant sequential (QoQ) decline in profitability
Limited pricing power due to intense competition from MNCs
Raw material price volatility impacting margins
👀 கவனிக்க வேண்டியவை
Investors should monitor the consolidated results to evaluate the performance of acquired subsidiaries like Unitop and Tristar, which are critical to the high-growth HPPC segment. Watch for management commentary on the sequential margin compression and the progress of the Rs 128 Cr ethoxylation capacity expansion.
Rossari Biotech Subsidiary Unistar Thai Sets Up 5000 MTPA Blending Facility in Thailand
Rossari Biotech's wholly-owned subsidiary, Unistar Thai Co. Limited, has established a new blending facility in Thailand with an installed capacity of 5,000 MTPA. Spanning approximately 1,860 square meters, the facility is designed to serve as a regional technical hub for the Southeast Asian market. This expansion allows for flexible manufacturing of powders, granules, and liquids, enabling the company to provide customized formulations locally. The move follows the 100% acquisition of Unistar in December 2024 and is expected to enhance supply chain resilience and operational efficiency.
முக்கிய அம்சங்கள்
Installed capacity of 5,000 MTPA at the new Thailand blending facilityFacility covers a land area of approximately 1,860 square metersStrategic regional technical hub for the Southeast Asian market to provide customized formulationsFlexible manufacturing capabilities across powders, granules, and liquids with dedicated storage for surfactantsFollow-up to the 100% equity acquisition of Unistar Thai Co. Limited completed in December 2024
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of this facility as it marks a significant step in Rossari's international expansion and localized manufacturing strategy. Positive impact on margins and market share in Southeast Asia is expected over the medium term.
Rossari Biotech Schedules 17th AGM for July 20, 2026; Sets July 10 as Dividend Record Date
Rossari Biotech Limited has scheduled its 17th Annual General Meeting (AGM) for July 20, 2026, to be conducted via video conferencing. The company has established July 10, 2026, as the record date to determine shareholder eligibility for the dividend for the financial year 2025-26. If approved at the AGM, the dividend will be disbursed within 10 working days from the meeting date. Furthermore, July 13, 2026, has been fixed as the cut-off date for participating in the electronic voting process.
முக்கிய அம்சங்கள்
17th Annual General Meeting (AGM) to be held on Monday, July 20, 2026, at 11:00 A.M. IST.Record date for determining dividend entitlement for FY 2025-26 is Friday, July 10, 2026.Dividend payment will be completed within 10 working days from the conclusion of the AGM, subject to shareholder approval.Cut-off date for remote e-voting and e-voting during the AGM is fixed as Monday, July 13, 2026.The dividend pertains to equity shares with a face value of Rs. 2/- each.
👀 கவனிக்க வேண்டியவை
Investors interested in receiving the dividend should ensure they hold the company's shares by the record date of July 10, 2026. Shareholders are also encouraged to participate in the e-voting process starting from the cut-off date of July 13.
Rossari Biotech Faces Legal Challenge to Unitop Chemicals Arbitration Award
Rossari Biotech has been served a petition by the former shareholders of its material subsidiary, Unitop Chemicals Private Limited, challenging a previous arbitration award. The Sellers filed the petition under Section 34 of the Arbitration and Conciliation Act, 1996, on June 04, 2026, contesting the final award issued on January 21, 2026. This dispute originates from the Share Purchase Agreement (SPA) signed on June 02, 2021, for the acquisition of Unitop. The ongoing litigation adds a layer of legal uncertainty regarding the final settlement terms of this material acquisition.
முக்கிய அம்சங்கள்
Sellers of Unitop Chemicals challenged the Arbitral Tribunal's final award dated January 21, 2026.The petition was served to Rossari Biotech on June 04, 2026, under Section 34 of the Arbitration and Conciliation Act.The dispute relates to the Share Purchase Agreement (SPA) executed on June 02, 2021.Unitop Chemicals is classified as a material unlisted subsidiary of Rossari Biotech Limited.The challenge indicates that the legal resolution regarding the acquisition terms is not yet finalized.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of this litigation as it may affect the final cash outflow or valuation adjustments related to the Unitop acquisition. No immediate portfolio changes are recommended, but the legal contingency should be factored into the company's risk profile.
Rossari Biotech to Grant 8.30 Lakh ESOPs at Rs 537; Re-appoints Independent Director
Rossari Biotech's board has approved the grant of 830,050 stock options under its 2019 ESOP plan at an exercise price of Rs 537 per share. The options follow a staggered vesting schedule over four years (20%, 20%, 20%, and 40%) and are exercisable within five years of vesting. Additionally, the board has recommended the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second three-year term starting October 21, 2026. These actions reflect the company's focus on talent retention and board continuity.
முக்கிய அம்சங்கள்
Grant of 830,050 stock options to eligible employees under the ESOP 2019 scheme.Exercise price for the options is fixed at Rs 537 per share.Vesting schedule is spread over 4 years: 20% annually for 3 years and 40% in the 4th year.Re-appointment of Ms. Esha Padmanabhan Achan as Independent Director for a 3-year term until October 2029.Ms. Achan brings 33 years of senior management experience from companies like Glenmark and Bajaj.
👀 கவனிக்க வேண்டியவை
Investors should monitor the potential equity dilution resulting from the 8.30 lakh shares and view the board re-appointment as a sign of governance stability.
Rossari Biotech Reports Record Q4 Revenue of ₹685 Cr; FY26 Revenue Up 15% to ₹2,396 Cr
Rossari Biotech achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, with revenue growing 18% YoY to ₹684.9 crore. For the full year FY26, the company reported a 15% revenue growth to ₹2,396.4 crore, supported by strong volume growth across HPPC, Textiles, and Animal Health segments. While overall EBITDA margins contracted slightly to 11.9% due to raw material volatility, the core B2B business maintained a robust 14% margin. Management has guided for at least 15% growth in FY27 with margins expected to stabilize between 12-13%.
முக்கிய அம்சங்கள்
Q4 FY26 marked record quarterly performance with revenue of ₹684.9 crore and EBITDA of ₹77.3 crore.Full-year FY26 revenue grew 15% to ₹2,396.4 crore, primarily driven by volume growth and an 11% increase in exports.Ethoxylation capacity at Dahej (Unitop) was expanded to 66,000 MTPA to enhance supply reliability.Core B2B operations delivered a healthy 14% EBITDA margin, offsetting losses in the subdued B2C and institutional segments.Company is re-evaluating and re-phasing its ₹192 crore CAPEX plan to align with evolving market conditions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to pass on raw material price hikes and the scaling of its new R&D and ethoxylation capacities. The shift toward higher-margin segments like pharma and biosurfactants provides a positive long-term outlook for margin expansion.
Rossari Biotech Reports Record Q4 FY26 Revenue of ₹685 Cr, PAT Up 34% YoY
Rossari Biotech achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, driven by double-digit growth across all business segments including HPPC, TSC, and AHN. For the full year FY26, revenue grew 15.2% to ₹2,396.4 crore, though EBITDA margins slightly compressed to 11.9% from 12.7% due to raw material cost volatility. The company successfully commissioned an additional 15,000 MTPA ethoxylation capacity at Dahej, bringing the total to 66,000 MTPA. A dividend of ₹0.50 per share has been recommended for the fiscal year.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 18.2% YoY to ₹684.9 crore, the highest quarterly performance to date.Quarterly Net Profit (PAT) surged 33.7% YoY to ₹46.0 crore in Q4 FY26.Full-year FY26 Revenue reached ₹2,396.4 crore with a consolidated PAT of ₹149.2 crore.Commissioned 15,000 MTPA ethoxylation capacity at Dahej facility on March 31, 2026.Net Debt to Equity remains healthy at 0.21x despite ongoing capital expenditure.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to pass on raw material costs to recover margins and the scaling of the newly added ethoxylation capacity. The narrowing losses in the B2C segment and strong core B2B growth suggest a positive outlook for the specialty chemicals platform.
Rossari Biotech has approved its audited FY26 financial results and recommended a final dividend of Rs. 0.50 per share (25% of face value). The company is rescheduling its previously announced capacity expansion project, which will now be implemented in a phased manner over the next two years to align with market conditions. A new R&D facility has been established in Navi Mumbai to consolidate innovation efforts. Additionally, the board appointed industry veteran Mr. Udeypaul Singh Gill as an Independent Director for a three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of 25% (Rs. 0.50 per share) for the financial year ended March 31, 2026.Rescheduled the major capacity expansion project to a phased implementation over the next 24 months.Established a new Research and Development facility in Navi Mumbai, relocating operations from IIT Bombay.Appointed Mr. Udeypaul Singh Gill, a leader with 40+ years of experience, as an Independent Director.Allotted 8,250 equity shares under the ESOP 2019 plan at an exercise price of Rs. 425 per share.
👀 கவனிக்க வேண்டியவை
Investors should monitor the reasons behind the expansion delay and how the phased rollout affects revenue growth targets. The focus on R&D and the addition of a seasoned board member are positive for long-term strategic positioning.
Rossari Biotech Reschedules Subsidiary Capacity Expansion Over Next Two Years
Rossari Biotech has announced a rescheduling of the capacity expansion projects at its material subsidiaries, Unitop Chemicals Private Limited and Tristar Intermediates Private Limited. The investment plan, originally initiated in April 2025, is being re-evaluated due to evolving business requirements and market conditions. The implementation will now be undertaken in a phased manner over the next two years. While the strategic intent remains unchanged, the delay suggests a more cautious approach to capital expenditure.
முக்கிய அம்சங்கள்
Capacity expansion at Unitop Chemicals and Tristar Intermediates is being re-evaluated and rescheduled.Project implementation will now occur in a phased manner over the next 24 months.The delay is attributed to evolving business requirements and current market conditions.Overall strategic intent of the investment remains unchanged despite the timeline shift.
👀 கவனிக்க வேண்டியவை
Investors should monitor how this delay impacts the company's medium-term growth guidance and revenue targets. The phased approach may improve short-term cash flow but delays the full realization of scale benefits.
Rossari Biotech's material subsidiary, Unitop Chemicals Private Limited, has successfully commissioned the final 15,000 MTPA of its planned 30,000 MTPA ethoxylation expansion at its Dahej facility. This marks the completion of a multi-year expansion project, bringing Unitop's total installed ethoxylation capacity to 66,000 MTPA effective March 31, 2026. The increased capacity is expected to drive significant volume growth and strengthen the company's market position in specialty chemicals. Investors should expect enhanced revenue contributions from this subsidiary starting from the first quarter of FY27.
முக்கிய அம்சங்கள்
Successfully commissioned the remaining 15,000 MTPA ethoxylation capacity at the Dahej facility.Completion of the total planned 30,000 MTPA expansion project first announced in October 2023.Total installed ethoxylation capacity for subsidiary Unitop Chemicals now stands at 66,000 MTPA.The new capacity is operational as of March 31, 2026, aligning with the start of the new fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up in capacity utilization and its subsequent impact on the consolidated margins and top-line growth in upcoming quarterly results.
Rossari Biotech Infuses SAR 8 Million into Subsidiary Rossari International
Rossari Biotech Limited has announced a capital infusion of SAR 8 million into its wholly-owned subsidiary, Rossari International Limited Company. The investment involved subscribing to 8,000 shares at a face value of SAR 1,000 per share on February 18, 2026. This transaction follows previous intimations made by the company in November 2024 and October 2025. The move signifies the company's continued focus on scaling its international operations and footprint in the Middle East region.
முக்கிய அம்சங்கள்
Investment of SAR 8 million (Saudi Riyal) in Rossari International Limited Company.Acquisition of 8,000 shares at a face value of SAR 1,000 each.The target entity is a 100% wholly-owned subsidiary of Rossari Biotech.Follow-up to previous strategic expansion disclosures made in October 2025.
👀 கவனிக்க வேண்டியவை
Investors should view this as a commitment to international growth; monitor the subsidiary's contribution to consolidated revenue in future quarters. Maintain a long-term outlook as these capital infusions are part of a planned expansion strategy.
Rossari Biotech Wins Arbitration; Sellers' Put Option Claim for Unitop Chemicals Dismissed
Rossari Biotech has received a final arbitral award regarding a dispute with the former shareholders of its subsidiary, Unitop Chemicals. The Arbitral Tribunal dismissed the sellers' claim which sought to force Rossari to purchase the third tranche of shares via a Put Option. While the company's counterclaims were also dismissed, the financial liability is restricted to a tax refund of INR 97.91 lakhs plus 12% interest. This outcome is favorable as it prevents a potentially large mandatory cash outflow for share acquisition.
முக்கிய அம்சங்கள்
Arbitral Tribunal dismissed Sellers' claim to exercise a Put Option for the third tranche of Unitop Chemicals sharesCompany's counterclaims were dismissed, resulting in a limited financial liability of INR 97,90,617Rossari directed to pay the tax refund amount with 12% interest per annumArbitration costs are to be shared equally between Rossari and the SellersManagement confirms the award will not have any material impact on the company's financials
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive resolution as it removes the legal uncertainty and potential financial burden of a forced share purchase. No immediate action is required as the financial impact is negligible relative to the company's size.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
